1112 ET - BioNTech expects its Covid-19 booster sales to stay relatively stable even if the government narrows its recommendations of who needs the shot. The Centers for Disease Control is scheduled to vote in June on a new recommendation for who should get the Covid-19 booster, which could narrow it to high-risk groups only. BioNTech, which rose to prominence for its partnership with Pfizer during the Covid-19 pandemic, says during an analyst call that many of the people still getting the booster are in high-risk groups already. The majority of Covid vaccines in the U.S. are going to people who are older than 65 or immunocompromised, which accounts for about 20% of Americans, management says. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
May 05, 2025 11:13 ET (15:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。